검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD1 Monoclonal Antibody (Anti-PD1 Monoclonal Antibody) City of Hope Medical Center·Lung Non-Small Cell Carcinoma ORR 26.2%·t½ 7 h |
|---|---|
Overview Program | Anti-PD1 Monoclonal Antibody |
Overview Company | City of Hope Medical Center |
Overview Modality | ANTIBODY |
Overview Target | Lung Non-Small Cell Carcinoma |
Overview Indication | Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8 |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , which aims to stimulate the immune system against cancer cells, is not comparable to systemic and cytotoxic chemotherapy, which directly attacks and destroys malignant cells |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 7 h |
PK/PD Species | Cynomolgus monkey, Mouse |
PK/PD Animal (cat.) | Mouse, NHP, Monkey |
PK/PD Experiment | single-dose toxicology study |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | Mouse, NHP, Monkey |
Toxicology Major finding | Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody.. Certain immune-checkpoint inhibitors have a narrow therapeutic window (TW) as cancer therapeutics, and engineered dual-/multi-targeting agents could potentially widen the TW to bring true clinical benefits. We report a new rationally-designed bispecific-antibody (BsAb), HX009, simultaneously targeting PD1… |
Clinical Primary efficacy | ORR 26.2% |
Clinical ORR | 26.2% |
Clinical PFS | 3.5 |
Clinical OS | 9.0 |
Clinical Result source | ClinicalTrials.gov NCT04693234 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD1 Monoclonal Antibody (Anti-PD1 Monoclonal Antibody) City of Hope Medical Center·Lung Non-Small Cell Carcinoma ORR 26.2%·t½ 7 h |
|---|---|
Overview Program | Anti-PD1 Monoclonal Antibody |
Overview Company | City of Hope Medical Center |
Overview Modality | ANTIBODY |
Overview Target | Lung Non-Small Cell Carcinoma |
Overview Indication | Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8 |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , which aims to stimulate the immune system against cancer cells, is not comparable to systemic and cytotoxic chemotherapy, which directly attacks and destroys malignant cells |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 7 h |
PK/PD Species | Cynomolgus monkey, Mouse |
PK/PD Animal (cat.) | Mouse, NHP, Monkey |
PK/PD Experiment | single-dose toxicology study |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | Mouse, NHP, Monkey |
Toxicology Major finding | Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody.. Certain immune-checkpoint inhibitors have a narrow therapeutic window (TW) as cancer therapeutics, and engineered dual-/multi-targeting agents could potentially widen the TW to bring true clinical benefits. We report a new rationally-designed bispecific-antibody (BsAb), HX009, simultaneously targeting PD1… |
Clinical Primary efficacy | ORR 26.2% |
Clinical ORR | 26.2% |
Clinical PFS | 3.5 |
Clinical OS | 9.0 |
Clinical Result source | ClinicalTrials.gov NCT04693234 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교